|
More site info...
Biotech Values | Forum profile
|
|
Forum profile page for Biotech Values on http://investorshub.advfn.com.
This report page is the aggregated overview from a single forum: Biotech Values, located on the Message Board at http://investorshub.advfn.com.
This forum profile page summarizes the general forum statistics such as: Users Activity, Forum Activity, and Top Authors, which are reported in either a table or graph below for a given reporting time period.
Additional forum profile information for "Biotech Values" on the Message Board at http://investorshub.advfn.com is also shown in the following ways:
1) Latest Active Threads
2) Hot Threads for Last Week
Warning: These statistics are generated using 'best efforts' and can experience delays and reporting errors at times. Please note that such statistics do not constitute a forum's popularity and/or exact posting volumes at any given reporting period.
|
|
|
|
|
Posting activity on Biotech Values:
|
|
Week
|
Month
|
3 Months
|
|
Threads:
|
373
|
1,311
|
3,948
|
|
Post:
|
381
|
1,325
|
3,990
|
|
|
Biotech Values Posting activity graph:
|
Top authors during last week:
user's latest post:
[b] MNTA [i] ReadMeFirst [/i][/b]
Published (2009-11-07 18:44:45)
MNTA ReadMeFirst [Updates: 3Q09 financial results and CC transcript; liquidity and cash usage; the Lovenox plot may have thickened (Teva CC); Copaxone continues to clean Tysabri’s clock in US market; patent application re reverse engineering Copaxone (thanks, floblu); 3Q09 sales of branded Lovenox; M118 paper from Nov09 issue of Thrombosis and Hemostasis; revised table of major shareholders; revised table of recent biotech buyouts; index to...
user's latest post:
Thats OK - I only invest in stocks
Published (2009-11-06 16:03:49)
Thats OK - I only invest in stocks that I think have a chance to actually make me money.
user's latest post:
[b]Scientific Meeting Calendar[/b]
Published (2009-11-05 08:08:39)
Scientific Meeting Calendar NOTE: ANYONE MAY UPDATE THIS FILE Edits: Added entries for Gastro 2009, ASCB, SABCS OCTOBER 2009 American College of Chest Physicians - CHEST October 31 - November 5, 2009 San Diego, California http://www.chestnet.org/CHEST/program/about09.php NOVEMBER 2009 American College of Allergy, Asthma & Immunology - ACAAI November 5-11, 2009 Miami Beach, FL http://www.acaai.org/Member/Annual_Meeting/Annual+Meeting.htm...
user's latest post:
ZGEN 1. recothrom sales grew 40%...
Published (2009-11-05 17:58:13)
ZGEN 1. recothrom sales grew 40% QOQ. after adjusting for wholesale inventory unit sales were up 25% QOQ. guidance is narrowed to 28-30M for the year (i.e. 9-11M for Q4) 2. they are moving to prefilled fixed doses in the phase 2 lambda trial so there won't be any issues with dilution and potential for incorrect dosing. 3. there should be a steady flow of data from the phase 2 a open label part of the lambda trial early next year 4. in a...
user's latest post:
OT Health insurance - [/quote]...
Published (2009-11-07 18:34:18)
OT Health insurance - [/quote] So up the penalty or, better yet, make it a mandatory three-year waiting period for people to get health insurance after they first become eligible.[/quote] I would suggest that that has zero political reality. Can you imagine a politician telling a pleading cancer patient - no, no, you have knew the rule. ....
user's latest post:
Question on Orphan Drug...
Published (2009-11-07 21:28:33)
Question on Orphan Drug Designation (SNSS vs. CYCC) SNSS recently received orphan drug designation for voreloxin, its drug in Phase 2 trials for the treatment of AML. See: http://finance.yahoo.com/news/Sunesis-Voreloxin-Receives-prnews-819406007.html?x=0&.v=1 SNSS is currently testing the drug in Phase 2 in a single-agent study in newly-diagnosed elderly AML patients and also in combination with cytarabine in relapsed/refractory AML....
user's latest post:
Healthcare reform bill passes in...
Published (2009-11-07 23:25:24)
Healthcare reform bill passes in the House, the AP is reporting. WASHINGTON — Triumphant Democrats steered landmark health care legislation to the brink of passage in the House late Saturday night, spurred by a summons from President Barack Obama to "answer the call of history" and expand coverage to millions who lack it. After months of struggle, Speaker Nancy Pelosi projected confidence and likened the bill to the creation of...
user's latest post:
The folks at your fave chemgenex...
Published (2009-11-07 18:16:35)
The folks at your fave chemgenex are going to get their clocks cleaned by them and i believe they've been misling you (based on some of your comments). I'm not sure what you think Berger lied about. But the controversy with the board was about a subsidiary that owned some i.p. connected to the mTOR inhibitor. They exchanged shares for the subsidiary. Berger thought the payout should be more than they ended up getting. Whole thing...
user's latest post:
Blade, I would think that a...
Published (2009-11-07 23:44:18)
Blade, I would think that a victory with the vote being 220-215 today really means that we're all losers. Congrats
|
|
|
|
Latest active threads on Biotech Values::
No activity within last 3 months.
|
|
Hot threads for last week on Biotech Values::
Started 5 days, 9 hours ago (2009-11-04 00:14:31)
by DewDiligence
[quote]TEVA is quite good at getting generics approved. Why would they have
a problem this time? [/quote] Because they don’t have the technology to
fully characterize the constituents of a complex mixture such as Lovenox.
[quote] Why would they want a "branded" product rather than a generic?
[/quote] They wouldn’t—it’s clearly better for them to have a
substitutable generic. However, if the FDA ...
Started 4 days, 8 hours ago (2009-11-05 01:04:33)
by DewDiligence
VRUS: Confirmed on the AASLD webcast that PSI-879 and PSI-938 are prodrugs
of the monophosphate nucleotide, as posted in #msg-42335204. Regards, Dew
Link for VRUS AASLD webcast: http://investor.pharmasset.com/events.cfm Link
for AASLD webcast slides (see slide #39):
http://investor.pharmasset.com/common/downlo ad/download.cfm?companyid=VRUS&fileid=329458&filek ey=c67362a8-fc76-4ddb-bb0d-...
Started 3 days, 9 hours ago (2009-11-06 00:30:05)
by DewDiligence
[quote]She [Robyn Karnauskas] must be reading this board. [/quote] Pretty
high chance of that, IMO. You could tell that Craig Wheeler was not
expecting to be asked about Teva’s ANDA because his reply to Robyn’s
question was clearly unrehearsed. It’s a good sign that MNTA does not
prearrange the analysts’ questions on CC’s as some biotech companies
have been known to do.
Started 2 days, 13 hours ago (2009-11-06 20:43:07)
by randychub
Jbog - So would you agree Nimo work or would you say that it does not bind
well enough to work as stated by many on this board? Also for what ever
reason are H&N cancers in that area of the world easier to treat? I thought
that was true but why then 13% in the RT arm trials in nimo & 36% in RT
only with Erbitux? Nimo at 4 years - 34.7% in the nimotuzumab+RT arm were
alive compared to 13% in the ...
Started 2 days, 8 hours ago (2009-11-07 01:42:44)
by DewDiligence
Does This Bill Have a Weight Problem? [#msg-40769188 is a must-read
companion piece.] http://online.wsj.com/article/SB125755503417635101 .html
›NOVEMBER 7, 2009 By JANET ADAMY The 1,990-page health-care bill in the
House is one of the weightiest pieces of legislation on Capitol Hill. A
single-sided copy of it printed by The Wall Street Journal weighed 19.6
pounds, and stood 8.25 inches tall. If it...
Started 1 day, 16 hours ago (2009-11-07 17:33:04)
by bladerunner1717
jbog, She's an inveterate liar, nothing but a tart for the health insurers.
I'm sure the numbers are a fraud, just like everything else that she's said
(i.e. the death panels). But the bill is almost 2000 pages long, so we'll
have to wait for the reasoned rebuttals. On the political front: The House
Bill may come up for a vote as early as today. It will be close. At least
27 Dems have said that ...
Started 1 day, 16 hours ago (2009-11-07 17:46:09)
by DewDiligence
Covidien Completes Acquisition of ASPM [This deal was announced on 9/28/09;
the $12/sh cash buyout price is a 56% premium to ASPM’s closing price
before the announcement. COV is the 2007 healthcare spin-off from Tyco
International that is now domiciled in Ireland in order to reduce taxes.]
http://finance.yahoo.com/news/Covidien-Com pletes-bw-2386549786.html?x=0&.v=1
4:18 pm EST, Friday November 6,...
Started 1 day, 15 hours ago (2009-11-07 18:16:35)
by rkrw
The folks at your fave chemgenex may well get their clocks cleaned by them
and i believe they've been misling you (based on some of your comments).
I'm not sure what you think Berger lied about. But the controversy with the
board was about a subsidiary that owned some i.p. connected to the mTOR
inhibitor. They exchanged shares for the subsidiary. Berger thought the
payout should be more than they...
|
|
![Thread info: [quote][i]TEVA is quite good at getting generics approved.](/images/thp_r1581.gif "Thread info: [quote][i]TEVA is quite good at getting generics approved.")
Size: 513 bytes
![Customize "[quote][i]TEVA is quite good at getting generics approved. :: Biotech Values :: Investors Hub - Discussion Groups"](/images/cust_r0.gif "Customize \"[quote][i]TEVA is quite good at getting generics approved. :: Biotech Values :: Investors Hub - Discussion Groups\"")
